Everest Medicines Limited (HKG:1952)
28.90
-2.32 (-7.43%)
Sep 10, 2026, 11:59 AM HKT
Everest Medicines Revenue
Everest Medicines had revenue of 1.26B CNY in the half year ending December 31, 2025, with 977.06% growth. This brings the company's revenue in the last twelve months to 2.41B, up 182.91% year-over-year. In the year 2025, Everest Medicines had annual revenue of 1.71B with 141.51% growth.
Revenue (ttm)
2.41B CNY
Revenue Growth
+182.91%
P/S Ratio
3.95
Revenue / Employee
2.97M CNY
Employees
812
Market Cap
10.98B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.71B | 1.00B | 141.51% |
| Dec 31, 2024 | 706.68M | 580.75M | 461.16% |
| Dec 31, 2023 | 125.93M | 113.14M | 884.46% |
| Dec 31, 2022 | 12.79M | 12.74M | 23,588.89% |
| Dec 31, 2021 | 54.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| HBM Holdings | 1.40B |
| Ascentage Pharma Group International | 741.90M |
| Alphamab Oncology | 598.06M |
| Suzhou Ribo Life Science | 536.18M |
| CStone Pharmaceuticals | 490.92M |
| Nanjing Leads Biolabs | 246.16M |
| GenFleet Therapeutics (Shanghai) | 144.96M |
| Ascletis Pharma | 1.09M |
Everest Medicines News
- 22 days ago - Everest Medicines Earnings Call Transcript: H1 2026 - Transcripts
- 22 days ago - Everest Medicines Earnings release: H1 2026 - Filings
- 22 days ago - Everest Medicines Slides: H1 2026 - Filings
- 22 days ago - Everest Medicines Quarterly report: H1 2026 - Filings
- 3 months ago - LENZ Therapeutics Secures $85 Million Potential from Everest Medicines Deal - GuruFocus
- 3 months ago - Everest Medicines Acquires Rights To Develop And Commercialize VIZZ In Greater China - Nasdaq
- 3 months ago - LENZ Announces Everest Medicines' Acquisition of VIZZ Rights in Greater China - GuruFocus
- 3 months ago - Travere Therapeutics Partners with Everest Medicines for $1.14 Billion Kidney Drug Deal - GuruFocus